Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc (ADAP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
adap · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Adaptimmune Therapeutics plc (ADAP) measures how much investors pay for each dollar of the company's trailing earnings. ADAP's current PE ratio of N/A is calculated by dividing its stock price of $0.05 by its TTM earnings per share of -$0.58.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2012 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Adaptimmune Therapeutics plcYou ADAP | $75M | N/A | — | -$0.58 |
 Adlai Nortye Ltd. ANL | $543M | N/A | — | -$3.33 |
 Apollomics, Inc. APLM | $15M | N/A | — | -$7.57 |
 BioLineRx Ltd. BLRX | $14M | N/A | — | -$0.29 |
 Ernexa Therapeutics Inc. ERNA | $2M | N/A | — | -$55.83 |
 GeoVax Labs, Inc. GOVX | $1M | N/A | — | -$22.40 |
 Lunai Bioworks Inc. LNAI | $11M | N/A | — | -$86.27 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.28 | — | |
2023-12-31 FY2023 | — | $-0.57 | — | |
2022-12-31 FY2022 | — | $-1.03 | — | |
2021-12-31 FY2021 | — | $-1.01 | — | |
2020-12-31 FY2020 | — | $-0.91 | — | |
2019-12-31 FY2019 | — | $-1.31 | — | |
2018-12-31 FY2018 | — | $-0.98 | — | |
2017-12-31 FY2017 | — | $-0.80 | — | |
2016-12-31 FY2016 | — | $-1.01 | — | |
2015-06-30 FY2015 | — | $-0.60 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Adaptimmune Therapeutics plc (ADAP) measures how much investors pay for each dollar of the company's trailing earnings. ADAP's current PE ratio of N/A is calculated by dividing its stock price of $0.05 by its TTM earnings per share of -$0.58.
Frequently asked questions
ADAP pe ratio · 6 questionsADAP's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.05 and TTM EPS of -$0.58. Data sourced from Financial Modeling Prep via ADAP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Adaptimmune Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08